Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

1.

Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.

Roukens AH, Soonawala D, Joosten SA, de Visser AW, Jiang X, Dirksen K, de Gruijter M, van Dissel JT, Bredenbeek PJ, Visser LG.

PLoS One. 2011;6(12):e27753. doi: 10.1371/journal.pone.0027753. Epub 2011 Dec 7.

PMID:
22163273
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.

Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanesa-Thasan N, Feroldi E, Reid M.

Hum Vaccin. 2010 Nov;6(11):906-14. doi: 10.4161/hv.6.11.12854. Epub 2010 Nov 1.

PMID:
20864814
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.

Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG.

PLoS One. 2008 Apr 23;3(4):e1993. doi: 10.1371/journal.pone.0001993.

PMID:
18431480
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Review of the risks and benefits of yellow fever vaccination including some new analyses.

Monath TP.

Expert Rev Vaccines. 2012 Apr;11(4):427-48. doi: 10.1586/erv.12.6. Review.

PMID:
22551029
[PubMed - indexed for MEDLINE]
5.

Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.

Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J.

J Med Virol. 1998 Oct;56(2):159-67.

PMID:
9746073
[PubMed - indexed for MEDLINE]
6.

Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.

Rafferty E, Duclos P, Yactayo S, Schuster M.

Vaccine. 2013 Dec 2;31(49):5798-805. doi: 10.1016/j.vaccine.2013.09.030. Epub 2013 Sep 27. Review.

PMID:
24079979
[PubMed - indexed for MEDLINE]
7.

[Long term persistence of yellow fever neutralising antibodies in elderly persons].

Coulange Bodilis H, Benabdelmoumen G, Gergely A, Goujon C, Pelicot M, Poujol P, Consigny PH.

Bull Soc Pathol Exot. 2011 Oct;104(4):260-5. doi: 10.1007/s13149-011-0135-7. Epub 2011 Feb 18. French.

PMID:
21336654
[PubMed - indexed for MEDLINE]
8.

Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.

Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T.

Vaccine. 2011 Jun 20;29(28):4544-55. doi: 10.1016/j.vaccine.2011.04.055. Epub 2011 May 5. Review.

PMID:
21549787
[PubMed - indexed for MEDLINE]
9.

Yellow fever 17D vaccine safety and immunogenicity in the elderly.

Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L, Bedford P.

Hum Vaccin. 2005 Sep-Oct;1(5):207-14. Epub 2005 Sep 2.

PMID:
17012867
[PubMed - indexed for MEDLINE]
Free Article
10.

Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.

Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, Mulligan MJ, Fischer M, Staples JE.

Am J Trop Med Hyg. 2012 Dec;87(6):1112-5. doi: 10.4269/ajtmh.2012.12-0182. Epub 2012 Oct 29.

PMID:
23109371
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.

Camacho LA, de Aguiar SG, Freire Mda S, Leal Mda L, do Nascimento JP, Iguchi T, Lozana JA, Farias RH; Collaborative Group for the Study of Yellow Fever Vaccines.

Rev Saude Publica. 2005 Jun;39(3):413-20. Epub 2005 Jun 30.

PMID:
15997317
[PubMed - indexed for MEDLINE]
Free Article
12.

Yellow fever vaccine: past, present and future.

Roukens AH, Visser LG.

Expert Opin Biol Ther. 2008 Nov;8(11):1787-95. doi: 10.1517/14712598.8.11.1787 . Review.

PMID:
18847312
[PubMed - indexed for MEDLINE]
13.

Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.

Breugelmans JG, Lewis RF, Agbenu E, Veit O, Jackson D, Domingo C, Böthe M, Perea W, Niedrig M, Gessner BD, Yactayo S; YF AEFI group.

Vaccine. 2013 Apr 3;31(14):1819-29. doi: 10.1016/j.vaccine.2013.01.054. Epub 2013 Feb 7.

PMID:
23395587
[PubMed - indexed for MEDLINE]
14.

Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.

Jentes ES, Han P, Gershman MD, Rao SR, LaRocque RC, Staples JE, Ryan ET; Global TravEpiNet Consortium.

Am J Trop Med Hyg. 2013 May;88(5):954-61. doi: 10.4269/ajtmh.12-0463. Epub 2013 Mar 4.

PMID:
23458961
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.

Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, Levesque P, Bowick GC, Morin M, Fowler E, Trent DW.

Vaccine. 2010 May 14;28(22):3827-40. doi: 10.1016/j.vaccine.2010.03.023. Epub 2010 Mar 26.

PMID:
20347059
[PubMed - indexed for MEDLINE]
16.

Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.

Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, Pastor-Cauna G, Echevarria C, Laguna-Torres VA, Samame BK, Baldeon ME, Burans JP, Olson JG, Bedford P, Kitchener S, Monath TP.

Am J Trop Med Hyg. 2005 Feb;72(2):189-97.

PMID:
15741556
[PubMed - indexed for MEDLINE]
Free Article
17.

Safety of the yellow Fever vaccine: a retrospective study.

Nordin JD, Parker ED, Vazquez-Benitez G, Kharbanda EO, Naleway A, Marcy SM, Molitor B, Kuckler L, Baggs J.

J Travel Med. 2013 Nov-Dec;20(6):368-73. doi: 10.1111/jtm.12070. Epub 2013 Oct 10.

PMID:
24118538
[PubMed - indexed for MEDLINE]
18.

Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study.

Kernéis S, Launay O, Ancelle T, Iordache L, Naneix-Laroche V, Méchaï F, Fehr T, Leroy JP, Issartel B, Dunand J, van der Vliet D, Wyplosz B, Consigny PH, Hanslik T.

Arthritis Care Res (Hoboken). 2013 Sep;65(9):1522-8. doi: 10.1002/acr.22021.

PMID:
23554297
[PubMed - indexed for MEDLINE]
19.

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, Bedford P, Lang J, Quentin-Millet MJ, Monath TP.

Hum Vaccin. 2006 Mar-Apr;2(2):60-7. Epub 2006 Mar 15.

PMID:
17012873
[PubMed - indexed for MEDLINE]
Free Article
20.

Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial.

Camacho LA, Freire Mda S, Leal Mda L, Aguiar SG, Nascimento JP, Iguchi T, Lozana Jde A, Farias RH; Collaborative Group for the Study of Yellow Fever Vaccines.

Rev Saude Publica. 2004 Oct;38(5):671-8. Epub 2004 Oct 18.

PMID:
15499438
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk